These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8369005)

  • 1. Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers.
    Hutt V; Janik F; Kappler J; Pabst G; Ravelli V; Maccari M; Jaeger H
    Arzneimittelforschung; 1993 Jul; 43(7):737-43. PubMed ID: 8369005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.
    Scheiwe MW; Lankhaar G; Kleinbloesem CH
    Arzneimittelforschung; 1996 Oct; 46(10):960-3. PubMed ID: 8931888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and pharmacokinetics of a new sustained-release formulation of diltiazem.
    Thiercelin JF; Necciari J; Caplain H; Cournot A; Combes M; Desmolin H; Flouvat B
    J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S31-7. PubMed ID: 1706011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of two tablet preparations of diltiazem in healthy volunteers.
    De Bernardis E; Candido P; Lorefice R; Picari M; Rizza V
    Arzneimittelforschung; 1992 Jan; 42(1):25-7. PubMed ID: 1586376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration.
    Sista S; Lai JC; Eradiri O; Albert KS
    J Clin Pharmacol; 2003 Oct; 43(10):1149-57. PubMed ID: 14517197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age.
    Bianchetti G; Billy S; Ascalone V; Saivin S; Houin G; Rosenzweig P
    Int J Clin Pharmacol Ther; 1996 May; 34(5):195-201. PubMed ID: 8738855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo performance of controlled release pellets of diltiazem HCl.
    Nisarur-ur-Rahman ; K H Y; Jia Woei W
    Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers.
    Korhonen O; Kanerva H; Vidgren M; Urtti A; Ketolainen J
    J Control Release; 2004 Mar; 95(3):515-20. PubMed ID: 15023462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of concomitant colestipol hydrochloride administration on the bioavailability of diltiazem from immediate- and sustained-release formulations.
    Turner SW; Jungbluth GL; Knuth DW
    Biopharm Drug Dispos; 2002 Dec; 23(9):369-77. PubMed ID: 12469330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers.
    Bianchetti G; Dubruc C; Sultana V; Houin G; Rosenzweig P
    Eur J Clin Pharmacol; 1995; 48(3-4):259-64. PubMed ID: 7589051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers.
    Höglund P; Nilsson LG
    Ther Drug Monit; 1989 Sep; 11(5):551-7. PubMed ID: 2815230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects.
    Ziemniak J; Colligon I; Heald D
    Clin Ther; 1992; 14(2):158-65. PubMed ID: 1611640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V; Della Paschoa O
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):418-25. PubMed ID: 9352390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers.
    Höglund P; Nilsson LG
    Ther Drug Monit; 1989 Sep; 11(5):558-66. PubMed ID: 2815231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers.
    Guimont S; Landriault H; Klischer K; Grace M; Lambert C; Caillé G; Gossard D; Russell A; Raymond M; Hutchings E
    Biopharm Drug Dispos; 1993 Dec; 14(9):767-78. PubMed ID: 8298070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bioavailability of diltiazem in prolonged-release oral preparations.
    Quiroga PA; Yuln GV; Palummo M; Cingolani A; Dall LL; Volonté MG
    Drug Dev Ind Pharm; 2001 Nov; 27(10):1099-106. PubMed ID: 11794812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets.
    Leeuwenkamp OR; Visscher HW; Mensink CK; Jonkman JH
    Eur J Clin Pharmacol; 1994; 46(3):243-7. PubMed ID: 8070505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bioavailability and pharmacodynamics of diltiazem from two pharmaceutical preparations.
    Dange SV; Nandal DH; Gokhale VS; Shah KU; Kadam DB
    Indian J Physiol Pharmacol; 1992 Jul; 36(3):205-8. PubMed ID: 1473854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.
    Caillé G; Boucher S; Spénard J; Lakhani Z; Russell A; Thiffault J; Grace MG
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):75-80. PubMed ID: 1936065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.